1
|
Dobrucki IT, Miskalis A, Nelappana M, Applegate C, Wozniak M, Czerwinski A, Kalinowski L, Dobrucki LW. Receptor for advanced glycation end-products: Biological significance and imaging applications. WILEY INTERDISCIPLINARY REVIEWS. NANOMEDICINE AND NANOBIOTECHNOLOGY 2024; 16:e1935. [PMID: 37926944 DOI: 10.1002/wnan.1935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Revised: 09/25/2023] [Accepted: 10/09/2023] [Indexed: 11/07/2023]
Abstract
The receptor for advanced glycation end-products (RAGE or AGER) is a transmembrane, immunoglobulin-like receptor that, due to its multiple isoform structures, binds to a diverse range of endo- and exogenous ligands. RAGE activation caused by the ligand binding initiates a cascade of complex pathways associated with producing free radicals, such as reactive nitric oxide and oxygen species, cell proliferation, and immunoinflammatory processes. The involvement of RAGE in the pathogenesis of disorders such as diabetes, inflammation, tumor progression, and endothelial dysfunction is dictated by the accumulation of advanced glycation end-products (AGEs) at pathologic states leading to sustained RAGE upregulation. The involvement of RAGE and its ligands in numerous pathologies and diseases makes RAGE an interesting target for therapy focused on the modulation of both RAGE expression or activation and the production or exogenous administration of AGEs. Despite the known role that the RAGE/AGE axis plays in multiple disease states, there remains an urgent need to develop noninvasive, molecular imaging approaches that can accurately quantify RAGE levels in vivo that will aid in the validation of RAGE and its ligands as biomarkers and therapeutic targets. This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Diagnostic Tools > Biosensing.
Collapse
Affiliation(s)
- Iwona T Dobrucki
- Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
- Beckman Institute for Advanced Science and Technology, Urbana, Illinois, USA
- Department of Biomedical and Translational Sciences, Carle-Illinois College of Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
- Academy of Medical and Social Applied Sciences, Elblag, Poland
| | - Angelo Miskalis
- Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
| | - Michael Nelappana
- Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
- Beckman Institute for Advanced Science and Technology, Urbana, Illinois, USA
| | - Catherine Applegate
- Beckman Institute for Advanced Science and Technology, Urbana, Illinois, USA
- Cancer Center at Illinois, Urbana, Illinois, USA
| | - Marcin Wozniak
- Beckman Institute for Advanced Science and Technology, Urbana, Illinois, USA
- Division of Medical Laboratory Diagnostics-Fahrenheit Biobank BBMRI.pl, Medical University of Gdansk, Gdansk, Poland
| | - Andrzej Czerwinski
- Beckman Institute for Advanced Science and Technology, Urbana, Illinois, USA
| | - Leszek Kalinowski
- Beckman Institute for Advanced Science and Technology, Urbana, Illinois, USA
- Division of Medical Laboratory Diagnostics-Fahrenheit Biobank BBMRI.pl, Medical University of Gdansk, Gdansk, Poland
- BioTechMed Centre, Department of Mechanics of Materials and Structures, Gdansk University of Technology, Gdansk, Poland
| | - Lawrence W Dobrucki
- Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
- Beckman Institute for Advanced Science and Technology, Urbana, Illinois, USA
- Department of Biomedical and Translational Sciences, Carle-Illinois College of Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
- Cancer Center at Illinois, Urbana, Illinois, USA
- Division of Medical Laboratory Diagnostics-Fahrenheit Biobank BBMRI.pl, Medical University of Gdansk, Gdansk, Poland
| |
Collapse
|
2
|
Mao Y, Ren J, Yang L. Advances of nanomedicine in treatment of atherosclerosis and thrombosis. ENVIRONMENTAL RESEARCH 2023; 238:116637. [PMID: 37482129 DOI: 10.1016/j.envres.2023.116637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Revised: 06/17/2023] [Accepted: 07/10/2023] [Indexed: 07/25/2023]
Abstract
Atherosclerosis (AS) is a chronic inflammatory vascular disease. Myocardial ischemia originated from AS is the main cause of cardiovascular diseases, one of the major factors contributing to the global disease burden. AS is typically quiescent until occurrence of plaque rupture and thrombosis, leading to acute coronary syndrome and sudden death. Currently, clinical diagnostic techniques suffer from major pitfalls including lack of accuracy and specificity, which makes it rather difficult for drugs to directly target plaques to achieve therapeutic effect. Therefore, how to accurately diagnose and effectively intervene vulnerable AS plaques to achieve accurate delivery of drugs has become an urgent and evolving clinical problem. With the rapid development of nanomedicine and nanomaterials, nanotechnology has shown unique advantages in monitoring vulnerable plaques and thrombus and improving drug efficacy. Recent studies have shown that application of nanoparticle drug delivery system can booster the safety and effectiveness of drug therapy, and molecular imaging technology and nanomedicine also exhibit high clinical application potentials in disease diagnosis. Therefore, nanotechnology provides another promising avenue for diagnosis and treatment of AS and thrombosis, and has shown excellent performance in the development of targeted drug therapy and biomaterials. In this review, the research progress, challenges and prospects of nanotechnology in AS and thrombosis are discussed, expecting to provide new ideas for the prevention, diagnosis and treatment of AS and thrombosis.
Collapse
Affiliation(s)
- Yu Mao
- Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China
| | - Jun Ren
- Department of Cardiology and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, China
| | - Lifang Yang
- Department of Anesthesiology, Xi'an Children Hospital, Xi'an, China.
| |
Collapse
|
3
|
Abstract
PURPOSE OF REVIEW This review presents the current state of imaging approaches that enable real-time molecular imaging in the interventional suite and discusses the potential future use of integrated nuclear imaging and fluoroscopy for intraprocedural guidance in the evaluation and treatment of both cardiovascular and oncological diseases. RECENT FINDINGS Although there are no commercially available real-time hybrid nuclear imaging devices that are approved for use in the interventional suite, prototype open gantry hybrid nuclear imaging and x-ray c-arm imaging systems and theranostic catheter for location radiotracer detection are currently undergoing development and testing by multiple groups. The integration of physiological and molecular targeted nuclear imaging for real-time delivery of targeted theranostics in the interventional laboratory may enable more personalized care for a wide variety of cardiovascular procedures and improve patient outcomes.
Collapse
|
4
|
Varani M, Galli F, Bentivoglio V, Signore A. Particles and nanoparticles in nuclear medicine: Basic principles and instrumentation. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00079-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
5
|
Panizzi P, Krohn-Grimberghe M, Keliher E, Ye YX, Grune J, Frodermann V, Sun Y, Muse CG, Bushey K, Iwamoto Y, van Leent MMT, Meerwaldt A, Toner YC, Munitz J, Maier A, Soultanidis G, Calcagno C, Pérez-Medina C, Carlucci G, Riddell KP, Barney S, Horne G, Anderson B, Maddur-Appajaiah A, Verhamme IM, Bock PE, Wojtkiewicz GR, Courties G, Swirski FK, Church WR, Walz PH, Tillson DM, Mulder WJM, Nahrendorf M. Multimodal imaging of bacterial-host interface in mice and piglets with Staphylococcus aureus endocarditis. Sci Transl Med 2021; 12:12/568/eaay2104. [PMID: 33148623 DOI: 10.1126/scitranslmed.aay2104] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2019] [Revised: 05/05/2020] [Accepted: 09/16/2020] [Indexed: 12/24/2022]
Abstract
Acute bacterial endocarditis is a rapid, difficult to manage, and frequently lethal disease. Potent antibiotics often cannot efficiently kill Staphylococcus aureus that colonizes the heart's valves. S. aureus relies on virulence factors to evade therapeutics and the host's immune response, usurping the host's clotting system by activating circulating prothrombin with staphylocoagulase and von Willebrand factor-binding protein. An insoluble fibrin barrier then forms around the bacterial colony, shielding the pathogen from immune cell clearance. Targeting virulence factors may provide previously unidentified avenues to better diagnose and treat endocarditis. To tap into this unused therapeutic opportunity, we codeveloped therapeutics and multimodal molecular imaging to probe the host-pathogen interface. We introduced and validated a family of small-molecule optical and positron emission tomography (PET) reporters targeting active thrombin in the fibrin-rich environment of bacterial colonies. The imaging agents, based on the clinical thrombin inhibitor dabigatran, are bound to heart valve vegetations in mice. Using optical imaging, we monitored therapy with antibodies neutralizing staphylocoagulase and von Willebrand factor-binding protein in mice with S. aureus endocarditis. This treatment deactivated bacterial defenses against innate immune cells, decreased in vivo imaging signal, and improved survival. Aortic or tricuspid S. aureus endocarditis in piglets was also successfully imaged with clinical PET/magnetic resonance imaging. Our data map a route toward adjuvant immunotherapy for endocarditis and provide efficient tools to monitor this drug class for infectious diseases.
Collapse
Affiliation(s)
- Peter Panizzi
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Marvin Krohn-Grimberghe
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA.,University Heart Center Freiburg, 79106 Freiburg, Germany
| | - Edmund Keliher
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Yu-Xiang Ye
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Jana Grune
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Vanessa Frodermann
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Yuan Sun
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Charlotte G Muse
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | | | - Yoshiko Iwamoto
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Mandy M T van Leent
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Anu Meerwaldt
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Yohana C Toner
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Jazz Munitz
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Alexander Maier
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Georgios Soultanidis
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Claudia Calcagno
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Carlos Pérez-Medina
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.,Centro Nacional de Investigaciones Cardivasculares, 28029 Madrid, Spain
| | - Giuseppe Carlucci
- Bernard and Irene Schwarz Center for Biomedical Imaging, New York University, New York, NY 10016, USA
| | - Kay P Riddell
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
| | - Sharron Barney
- Department of Clinical Science, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
| | - Glenn Horne
- Department of Clinical Science, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
| | - Brian Anderson
- Swine Research and Education Center, Department of Animal Sciences, Auburn University, Auburn, AL 36849, USA
| | - Ashoka Maddur-Appajaiah
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
| | - Ingrid M Verhamme
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
| | - Paul E Bock
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
| | - Gregory R Wojtkiewicz
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Gabriel Courties
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Filip K Swirski
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | | | - Paul H Walz
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
| | - D Michael Tillson
- Department of Clinical Science, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
| | - Willem J M Mulder
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.,Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.,Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, 5612 AZ Eindhoven, Netherlands
| | - Matthias Nahrendorf
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA. .,Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.,Department of Internal Medicine I, University Hospital Würzburg, 97080 Würzburg, Germany
| |
Collapse
|
6
|
Si-Mohamed SA, Sigovan M, Hsu JC, Tatard-Leitman V, Chalabreysse L, Naha PC, Garrivier T, Dessouky R, Carnaru M, Boussel L, Cormode DP, Douek PC. In Vivo Molecular K-Edge Imaging of Atherosclerotic Plaque Using Photon-counting CT. Radiology 2021; 300:98-107. [PMID: 33944628 PMCID: PMC8217298 DOI: 10.1148/radiol.2021203968] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Background Macrophage burden is a major factor in the risk of atherosclerotic plaque rupture, and its evaluation remains challenging with molecular noninvasive imaging approaches. Photon-counting CT (PCCT) with k-edge imaging aims to allow for the specific detection of macrophages using gold nanoparticles. Purpose To perform k-edge imaging in combination with gold nanoparticles to detect and quantify the macrophage burden within the atherosclerotic aortas of rabbits. Materials and Methods Atherosclerotic and control New Zealand white rabbits were imaged before and at several time points up to 2 days after intravenous injection of gold nanoparticles (3.5 mL/kg, 65 mg gold per milliliter). Aortic CT angiography was performed at the end of the follow-up using an intravenous injection of an iodinated contrast material. Gold k-edge and conventional CT images were reconstructed for qualitative and quantitative assessment of the macrophage burden. PCCT imaging results were compared with findings at histologic examination, quantitative histomorphometry, transmission electron microscopy, and quantitative inductively coupled plasma optical emission spectrometry. Pearson correlations between the macrophage area measured in immunostained sections and the concentration of gold and attenuation measured in the corresponding PCCT sections were calculated. Results Seven rabbits with atherosclerosis and four control rabbits without atherosclerosis were analyzed. In atherosclerotic rabbits, calcifications were observed along the aortic wall before injection. At 2 days after injection of gold nanoparticles, only gold k-edge images allowed for the distinction of plaque enhancement within calcifications and for lumen enhancement during angiography. A good correlation was observed between the gold concentration measured within the wall and the macrophage area in 35 plaques (five per rabbit) (r = 0.82; 95% CI: 0.67, 0.91; P < .001), which was higher than that observed on conventional CT images (r = 0.41; 95% CI: 0.09, 0.65; P = .01). Transmission electron microscopy and inductively coupled plasma optical emission spectrometry analyses confirmed the gold k-edge imaging findings. Conclusion Photon-counting CT with gold nanoparticles allowed for the noninvasive evaluation of both molecular and anatomic information in vivo in rabbits with atherosclerotic plaques. Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Leiner in this issue.
Collapse
Affiliation(s)
- Salim A Si-Mohamed
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Monica Sigovan
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Jessica C Hsu
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Valérie Tatard-Leitman
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Lara Chalabreysse
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Pratap C Naha
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Thibaut Garrivier
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Riham Dessouky
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Miruna Carnaru
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Loic Boussel
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - David P Cormode
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Philippe C Douek
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| |
Collapse
|
7
|
Gropler RJ. Imaging Myocardial Metabolism. Mol Imaging 2021. [DOI: 10.1016/b978-0-12-816386-3.00083-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
8
|
Wu YL. Cardiac MRI Assessment of Mouse Myocardial Infarction and Regeneration. Methods Mol Biol 2021; 2158:81-106. [PMID: 32857368 DOI: 10.1007/978-1-0716-0668-1_8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Small animal models are indispensable for cardiac regeneration research. Studies in mouse and rat models have provided important insights into the etiology and mechanisms of cardiovascular diseases and accelerated the development of therapeutic strategies. It is vitally important to be able to evaluate the therapeutic efficacy and have reliable surrogate markers for therapeutic development for cardiac regeneration research. Magnetic resonance imaging (MRI), a versatile and noninvasive imaging modality with excellent penetration depth, tissue coverage, and soft-tissue contrast, is becoming a more important tool in both clinical settings and research arenas. Cardiac MRI (CMR) is versatile, noninvasive, and capable of measuring many different aspects of cardiac functions, and, thus, is ideally suited to evaluate therapeutic efficacy for cardiac regeneration. CMR applications include assessment of cardiac anatomy, regional wall motion, myocardial perfusion, myocardial viability, cardiac function assessment, assessment of myocardial infarction, and myocardial injury. Myocardial infarction models in mice are commonly used model systems for cardiac regeneration research. In this chapter, we discuss various CMR applications to evaluate cardiac functions and inflammation after myocardial infarction.
Collapse
Affiliation(s)
- Yijen L Wu
- Department of Developmental Biology, Rangos Research Center Animal Imaging Core, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
| |
Collapse
|
9
|
Abstract
The term diabetic cardiomyopathy is defined as the presence of abnormalities in myocardial structure and function that occur in the absence of, or in addition to, well-established cardiovascular risk factors. A key contributor to this abnormal structural-functional relation is the complex interplay of myocardial metabolic remodeling, defined as the loss the flexibility in myocardial substrate metabolism and its downstream detrimental effects, such as mitochondrial dysfunction, inflammation, and fibrosis. In parallel with the growth in understanding of these biological underpinnings has been developmental advances in imaging tools such as positron emission tomography and magnetic resonance imaging and spectroscopy that permit the detection and in many cases quantification, of the processes that typifies the myocardial metabolic remodeling in diabetic cardiomyopathy. The imaging readouts can be obtained in both preclinical models of diabetes mellitus and patients with diabetes mellitus facilitating the bi-directional movement of information between bench and bedside. Moreover, imaging biomarkers provided by these tools are now being used to enhance discovery and development of therapies designed to reduce the myocardial effects of diabetes mellitus through metabolic modulation. In this review, the use of these imaging tools in the patient with diabetes mellitus from a mechanistic, therapeutic effect, and clinical management perspective will be discussed.
Collapse
Affiliation(s)
- Linda R Peterson
- From the Cardiovascular Division, Department of Medicine (L.R.P.), Washington University School of Medicine, St Louis, MO
| | - Robert J Gropler
- Division of Radiological Sciences, Edward Mallinckrodt Institute of Radiology (R.J.G.), Washington University School of Medicine, St Louis, MO
| |
Collapse
|
10
|
Ultrasound molecular imaging: insights into cardiovascular pathology. J Echocardiogr 2020; 18:86-93. [PMID: 32056137 PMCID: PMC7244457 DOI: 10.1007/s12574-020-00463-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Revised: 01/16/2020] [Accepted: 01/27/2020] [Indexed: 01/06/2023]
Abstract
Similar to what has already occurred in cancer medicine, the management of cardiovascular conditions will likely be improved by non-invasive molecular imaging technologies that can provide earlier or more accurate diagnosis. These techniques are already having a positive impact in pre-clinical research by providing insight into pathophysiology or efficacy of new therapies. Contrast enhanced ultrasound (CEU) molecular imaging is a technique that relies on the ultrasound detection of targeted microbubble contrast agents to examine molecular or cellular events that occur at the blood pool-endothelial interface. CEU molecular imaging techniques have been developed that are able to provide unique information on atherosclerosis, ischemia reperfusion injury, angiogenesis, vascular inflammation, and thrombus formation. Accordingly, CEU has the potential to be used in a wide variety of circumstances to detect disease early or at the bedside, and to guide appropriate therapy based on vascular phenotype. This review will describe the physical basis for CEU molecular imaging, and the specific disease processes for the pre-clinical translational research experience.
Collapse
|
11
|
Hu J, Gorsak T, Martín Rodríguez E, Calle D, Muñoz‐Ortiz T, Jaque D, Fernández N, Cussó L, Rivero F, Aguilar Torres R, García Solé J, Mertelj A, Makovec D, Desco M, Lisjak D, Alfonso F, Sanz‐Rodríguez F, Ortgies DH. Magnetic Nanoplatelets for High Contrast Cardiovascular Imaging by Magnetically Modulated Optical Coherence Tomography. CHEMPHOTOCHEM 2019. [DOI: 10.1002/cptc.201900071] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Jie Hu
- Xiamen Institute of Rare-earth Materials, Haixi InstitutesChinese Academy of Sciences 258 Duishanxiheng Road, Jimei District Xiamen 361024, Fujian China
| | - Tanja Gorsak
- Jožef Stefan InstituteDepartment for Materials Synthesis Ljubljana 1000 Slovenia
- Jožef Stefan International Postgraduate School Ljubljana 1000 Slovenia
| | - Emma Martín Rodríguez
- Fluorescence Imaging Group, Departamento de Física AplicadaUniversidad Autónoma de Madrid C/ Francisco Tomás y Valiente 7 Madrid 28049 Spain
- Nanobiology GroupInstituto Ramón y Cajal de Investigación Sanitaria IRYCIS Ctra. Colmenar km. 9.100 Madrid 28034 Spain
| | - Daniel Calle
- Instituto de Investigación Sanitaria Gregorio Marañón Madrid 28007 Spain
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Madrid 28029 Spain
| | - Tamara Muñoz‐Ortiz
- Fluorescence Imaging Group Departamento de Física de MaterialesUniversidad Autónoma de Madrid C/ Francisco Tomás y Valiente 7 Madrid 28049 Spain
| | - Daniel Jaque
- Fluorescence Imaging Group Departamento de Física de MaterialesUniversidad Autónoma de Madrid C/ Francisco Tomás y Valiente 7 Madrid 28049 Spain
- Nanobiology GroupInstituto Ramón y Cajal de Investigación Sanitaria IRYCIS Ctra. Colmenar km. 9.100 Madrid 28034 Spain
| | - Nuria Fernández
- Fluorescence Imaging Group, Departamento de Fisiología Facultad de Medicina, Avda. Arzobispo Morcillo 2Universidad Autónoma de Madrid 28029 Madrid Spain
| | - Lorena Cussó
- Departamento de Bioingeniería e Ingeniería AeroespacialUniversidad Carlos III de Madrid 28911 Madrid Spain
- Instituto de Investigación Sanitaria Gregorio Marañón Madrid 28007 Spain
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Madrid 28029 Spain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) Madrid 28029 Spain
| | - Fernando Rivero
- Cardiology Department, Hospital Universitario de la Princesa, IIS-IPUniversidad Autónoma de Madrid Madrid 28006 Spain
| | - Río Aguilar Torres
- Cardiology Department, Hospital Universitario de la Princesa, IIS-IPUniversidad Autónoma de Madrid Madrid 28006 Spain
| | - José García Solé
- Fluorescence Imaging Group Departamento de Física de MaterialesUniversidad Autónoma de Madrid C/ Francisco Tomás y Valiente 7 Madrid 28049 Spain
| | - Alenka Mertelj
- Jožef Stefan Institute, Department for Complex Matter Ljubljana 1000 Slovenia
| | - Darko Makovec
- Jožef Stefan InstituteDepartment for Materials Synthesis Ljubljana 1000 Slovenia
| | - Manuel Desco
- Departamento de Bioingeniería e Ingeniería AeroespacialUniversidad Carlos III de Madrid 28911 Madrid Spain
- Instituto de Investigación Sanitaria Gregorio Marañón Madrid 28007 Spain
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Madrid 28029 Spain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) Madrid 28029 Spain
| | - Darja Lisjak
- Jožef Stefan InstituteDepartment for Materials Synthesis Ljubljana 1000 Slovenia
| | - Fernando Alfonso
- Cardiology Department, Hospital Universitario de la Princesa, IIS-IPUniversidad Autónoma de Madrid Madrid 28006 Spain
| | - Francisco Sanz‐Rodríguez
- Fluorescence Imaging Group, Departamento de BiologíaUniversidad Autónoma de Madrid Madrid 28049 Spain
| | - Dirk H. Ortgies
- Fluorescence Imaging Group Departamento de Física de MaterialesUniversidad Autónoma de Madrid C/ Francisco Tomás y Valiente 7 Madrid 28049 Spain
- Nanobiology GroupInstituto Ramón y Cajal de Investigación Sanitaria IRYCIS Ctra. Colmenar km. 9.100 Madrid 28034 Spain
| |
Collapse
|
12
|
Boutagy NE, Feher A, Alkhalil I, Umoh N, Sinusas AJ. Molecular Imaging of the Heart. Compr Physiol 2019; 9:477-533. [PMID: 30873600 DOI: 10.1002/cphy.c180007] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Multimodality cardiovascular imaging is routinely used to assess cardiac function, structure, and physiological parameters to facilitate the diagnosis, characterization, and phenotyping of numerous cardiovascular diseases (CVD), as well as allows for risk stratification and guidance in medical therapy decision-making. Although useful, these imaging strategies are unable to assess the underlying cellular and molecular processes that modulate pathophysiological changes. Over the last decade, there have been great advancements in imaging instrumentation and technology that have been paralleled by breakthroughs in probe development and image analysis. These advancements have been merged with discoveries in cellular/molecular cardiovascular biology to burgeon the field of cardiovascular molecular imaging. Cardiovascular molecular imaging aims to noninvasively detect and characterize underlying disease processes to facilitate early diagnosis, improve prognostication, and guide targeted therapy across the continuum of CVD. The most-widely used approaches for preclinical and clinical molecular imaging include radiotracers that allow for high-sensitivity in vivo detection and quantification of molecular processes with single photon emission computed tomography and positron emission tomography. This review will describe multimodality molecular imaging instrumentation along with established and novel molecular imaging targets and probes. We will highlight how molecular imaging has provided valuable insights in determining the underlying fundamental biology of a wide variety of CVDs, including: myocardial infarction, cardiac arrhythmias, and nonischemic and ischemic heart failure with reduced and preserved ejection fraction. In addition, the potential of molecular imaging to assist in the characterization and risk stratification of systemic diseases, such as amyloidosis and sarcoidosis will be discussed. © 2019 American Physiological Society. Compr Physiol 9:477-533, 2019.
Collapse
Affiliation(s)
- Nabil E Boutagy
- Department of Medicine, Yale Translational Research Imaging Center, Yale University School of Medicine, Section of Cardiovascular Medicine, New Haven, Connecticut, USA
| | - Attila Feher
- Department of Medicine, Yale Translational Research Imaging Center, Yale University School of Medicine, Section of Cardiovascular Medicine, New Haven, Connecticut, USA
| | - Imran Alkhalil
- Department of Medicine, Yale Translational Research Imaging Center, Yale University School of Medicine, Section of Cardiovascular Medicine, New Haven, Connecticut, USA
| | - Nsini Umoh
- Department of Medicine, Yale Translational Research Imaging Center, Yale University School of Medicine, Section of Cardiovascular Medicine, New Haven, Connecticut, USA
| | - Albert J Sinusas
- Department of Medicine, Yale Translational Research Imaging Center, Yale University School of Medicine, Section of Cardiovascular Medicine, New Haven, Connecticut, USA.,Yale University School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, Connecticut, USA
| |
Collapse
|
13
|
Lee KY, Chang K. Understanding Vulnerable Plaques: Current Status and Future Directions. Korean Circ J 2019; 49:1115-1122. [PMID: 31760703 PMCID: PMC6875591 DOI: 10.4070/kcj.2019.0211] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2019] [Revised: 09/30/2019] [Accepted: 10/07/2019] [Indexed: 01/19/2023] Open
Abstract
The main cause of acute myocardial infarction is plaque rupture accompanied by superimposed coronary thrombosis. Thin-cap fibroatheromas (TCFAs) have been suggested as a type of lesion with a vulnerability that can cause plaque rupture. However, not only the existence of a TCFA but also the fine and complex interactions of other anatomical and hemodynamic factors, such as microcalcification in the fibrous cap, cholesterol crystal-induced inflammasome activation, the apoptosis of intraplaque macrophages, and endothelial shear stress distribution should precede a clinical event caused by plaque rupture. Recent studies are being conducted to identify these mechanisms through molecular imaging and hemodynamic assessment using computational fluid dynamics, which will result in better clinical results through selective coronary interventions.
Collapse
Affiliation(s)
- Kwan Yong Lee
- Cardiovascular Center and Cardiology Division, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
| | - Kiyuk Chang
- Cardiovascular Center and Cardiology Division, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
| |
Collapse
|
14
|
Zeng Y, Zhu J, Wang J, Parasuraman P, Busi S, Nauli SM, Wáng YXJ, Pala R, Liu G. Functional probes for cardiovascular molecular imaging. Quant Imaging Med Surg 2018; 8:838-852. [PMID: 30306063 PMCID: PMC6177368 DOI: 10.21037/qims.2018.09.19] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Accepted: 09/17/2018] [Indexed: 12/26/2022]
Abstract
Cardiovascular diseases (CVDs) are a severely threatening disorder and frequently cause death in industrialized countries, posing critical challenges to modern research and medicine. Molecular imaging has been heralded as the solution to many problems encountered in individuals living with CVD. The use of probes in cardiovascular molecular imaging is causing a paradigmatic shift from regular imaging techniques, to future advanced imaging technologies, which will facilitate the acquisition of vital information at the cellular and molecular level. Advanced imaging for CVDs will help early detection of disease development, allow early therapeutic intervention, and facilitate better understanding of fundamental biological processes. To promote a better understanding of cardiovascular molecular imaging, this article summarizes the current developments in the use of molecular probes, highlighting some of the recent advances in probe design, preparation, and functional modification.
Collapse
Affiliation(s)
- Yun Zeng
- Department of Pharmacology, Xiamen Medical College, Xiamen 361008, China
| | - Jing Zhu
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China
| | - Junqing Wang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China
- Department of Imaging and Interventional Radiology, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR, China
| | - Paramanantham Parasuraman
- Departments of Microbiology, School of Life Sciences, Pondicherry University, Puducherry 605014, India
| | - Siddhardha Busi
- Departments of Microbiology, School of Life Sciences, Pondicherry University, Puducherry 605014, India
| | - Surya M. Nauli
- Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, California, USA
| | - Yì Xiáng J. Wáng
- Department of Imaging and Interventional Radiology, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR, China
| | - Rajasekharreddy Pala
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China
- Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, California, USA
| | - Gang Liu
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China
| |
Collapse
|
15
|
Abstract
The development of new methods to image the onset and progression of thrombosis is an unmet need. Non-invasive molecular imaging techniques targeting specific key structures involved in the formation of thrombosis have demonstrated the ability to detect thrombus in different disease state models and in patients. Due to its high concentration in the thrombus and its essential role in thrombus formation, the detection of fibrin is an attractive strategy for identification of thrombosis. Herein we provide an overview of recent and selected fibrin-targeted probes for molecular imaging of thrombosis by magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), and optical techniques. Emphasis is placed on work that our lab has explored over the last 15 years that has resulted in the progression of the fibrin-binding PET probe [64Cu]FBP8 from preclinical studies into human trials.
Collapse
Affiliation(s)
- Bruno L Oliveira
- Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW, Cambridge, UK.
| | | |
Collapse
|
16
|
Franchi F, Peterson KM, Paulmurugan R, Folmes C, Lanza IR, Lerman A, Rodriguez-Porcel M. Noninvasive Monitoring of the Mitochondrial Function in Mesenchymal Stromal Cells. Mol Imaging Biol 2017; 18:510-8. [PMID: 26865378 DOI: 10.1007/s11307-016-0929-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
PURPOSE Mitochondria are a gatekeeper of cell survival and mitochondrial function can be used to monitor cell stress. Here we validate a pathway-specific reporter gene to noninvasively image the mitochondrial function of stem cells. PROCEDURES We constructed a mitochondrial sensor with the firefly luciferase (Fluc) reporter gene driven by the NQO1 enzyme promoter. The sensor was introduced in stem cells and validated in vitro and in vivo, in a mouse model of myocardial ischemia/reperfusion (IR). RESULTS The sensor activity showed an inverse relationship with mitochondrial function (R (2) = -0.975, p = 0.025) and showed specificity and sensitivity for mitochondrial dysfunction. In vivo, NQO1-Fluc activity was significantly higher in IR animals vs. controls, indicative of mitochondrial dysfunction, and was corroborated by ex vivo luminometry. CONCLUSIONS Reporter gene imaging allows assessment of the biology of transplanted mesenchymal stromal cells (MSCs), providing important information that can be used to improve the phenotype and survival of transplanted stem cells.
Collapse
Affiliation(s)
- Federico Franchi
- Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA
| | - Karen M Peterson
- Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA
| | - Ramasamy Paulmurugan
- Department of Radiology and Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, Stanford, CA, USA
| | - Clifford Folmes
- Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA
| | - Ian R Lanza
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Amir Lerman
- Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA
| | - Martin Rodriguez-Porcel
- Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
| |
Collapse
|
17
|
Feher A, Sinusas AJ. Quantitative Assessment of Coronary Microvascular Function: Dynamic Single-Photon Emission Computed Tomography, Positron Emission Tomography, Ultrasound, Computed Tomography, and Magnetic Resonance Imaging. Circ Cardiovasc Imaging 2017; 10:CIRCIMAGING.117.006427. [PMID: 28794138 DOI: 10.1161/circimaging.117.006427] [Citation(s) in RCA: 108] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Accepted: 06/26/2017] [Indexed: 01/09/2023]
Abstract
A healthy, functional microcirculation in combination with nonobstructed epicardial coronary arteries is the prerequisite of normal myocardial perfusion. Quantitative assessment in myocardial perfusion and determination of absolute myocardial blood flow can be achieved noninvasively using dynamic imaging with multiple imaging modalities. Extensive evidence supports the clinical value of noninvasively assessing indices of coronary flow for diagnosing coronary microvascular dysfunction; in certain diseases, the degree of coronary microvascular impairment carries important prognostic relevance. Although, currently positron emission tomography is the most commonly used tool for the quantification of myocardial blood flow, other modalities, including single-photon emission computed tomography, computed tomography, magnetic resonance imaging, and myocardial contrast echocardiography, have emerged as techniques with great promise for determination of coronary microvascular dysfunction. The following review will describe basic concepts of coronary and microvascular physiology, review available modalities for dynamic imaging for quantitative assessment of coronary perfusion and myocardial blood flow, and discuss their application in distinct forms of coronary microvascular dysfunction.
Collapse
Affiliation(s)
- Attila Feher
- From the Section of Cardiovascular Medicine, Department of Internal Medicine (A.F., A.J.S.) and Department of Radiology and Biomedical Imaging (A.J.S.), Yale University School of Medicine, New Haven, CT
| | - Albert J Sinusas
- From the Section of Cardiovascular Medicine, Department of Internal Medicine (A.F., A.J.S.) and Department of Radiology and Biomedical Imaging (A.J.S.), Yale University School of Medicine, New Haven, CT.
| |
Collapse
|
18
|
Franchi F, Rodriguez-Porcel M. Noninvasive Assessment of Cell Fate and Biology in Transplanted Mesenchymal Stem Cells. Methods Mol Biol 2017; 1553:227-239. [PMID: 28229420 PMCID: PMC5589130 DOI: 10.1007/978-1-4939-6756-8_18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Recently, molecular imaging has become a conditio sine qua non for cell-based regenerative medicine. Developments in molecular imaging techniques, such as reporter gene technology, have increasingly enabled the noninvasive assessment of the fate and biology of cells after cardiovascular applications. In this context, bioluminescence imaging is the most commonly used imaging modality in small animal models of preclinical studies. Here, we present a detailed protocol of a reporter gene imaging approach for monitoring the viability and biology of Mesenchymal Stem Cells transplanted in a mouse model of myocardial ischemia reperfusion injury.
Collapse
Affiliation(s)
- Federico Franchi
- Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First St. SW, Rochester, 55905, MN, USA
| | - Martin Rodriguez-Porcel
- Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First St. SW, Rochester, 55905, MN, USA.
| |
Collapse
|
19
|
Centurión OA. Serum biomarkers and source of inflammation in acute coronary syndromes and percutaneous coronary interventions. CARDIOVASCULAR REVASCULARIZATION MEDICINE 2016; 17:119-28. [DOI: 10.1016/j.carrev.2016.01.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2015] [Revised: 01/05/2016] [Accepted: 01/13/2016] [Indexed: 11/17/2022]
|
20
|
|
21
|
Li X, Heber D, Rausch I, Beitzke D, Mayerhoefer ME, Rasul S, Kreissl M, Mitthauser M, Wadsak W, Hartenbach M, Haug A, Zhang X, Loewe C, Beyer T, Hacker M. Quantitative assessment of atherosclerotic plaques on (18)F-FDG PET/MRI: comparison with a PET/CT hybrid system. Eur J Nucl Med Mol Imaging 2016; 43:1503-12. [PMID: 26816195 PMCID: PMC4906060 DOI: 10.1007/s00259-016-3308-6] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2015] [Accepted: 01/05/2016] [Indexed: 01/05/2023]
Abstract
Purpose PET with 18F-FDG has the potential to assess vascular macrophage metabolism. 18F-FDG is most often used in combination with contrast-enhanced CT to localize increased metabolism to specific arterial lesions. Novel 18F-FDG PET/MRI hybrid imaging shows high potential for the combined evaluation of atherosclerotic plaques, due to the superior morphological conspicuity of plaque lesions. The purpose of this study was to evaluate the reliability and accuracy of 18F-FDG PET/MRI uptake quantification compared to PET/CT as a reference standard in patients with carotid atherosclerotic plaques. Methods The study group comprised 34 consecutive oncological patients with carotid plaques who underwent both PET/CT and PET/MRI with 18F-FDG on the same day. The presence of atherosclerotic plaques was confirmed by 3 T MRI scans. Maximum standardized uptake values (SUVmax) for carotid plaque lesions and the average SUV of the blood pool within the adjacent internal jugular vein were determined and target-to-blood ratios (TBRs, plaque to blood pool) were calculated. Results Atherosclerotic lesions with maximum colocalized focal FDG uptake were assessed in each patient. SUVmax values of carotid plaque lesions were significantly lower on PET/MRI than on PET/CT (2.3 ± 0.6 vs. 3.1 ± 0.6; P < 0.01), but were significantly correlated between PET/CT and PET/MRI (Spearman’s r = 0.67, P < 0.01). In contrast, TBRmax values of plaque lesions were similar on PET/MRI and on PET/CT (2.2 ± 0.3 vs. 2.2 ± 0.3; P = 0.4), and again were significantly correlated between PET/MRI and PET/CT (Spearman’s r = 0.73, P < 0.01). Considering the increasing trend in SUVmax and TBRmax values from early to delayed imaging time-points on PET/CT and PET/MRI, respectively, with continuous clearance of radioactivity from the blood, a slight underestimation of TBRmax values may also be expected with PET/MRI compared with PET/CT. Conclusion SUVmax and TBRmax values are widely accepted reference parameters for estimation of the radioactivity of atherosclerotic plaques on PET/CT. However, due to a systematic underestimation of SUVmax and TBRmax with PET/MRI, the optimal cut-off values indicating the presence of inflamed plaque tissue need to be newly defined for PET/MRI.
Collapse
Affiliation(s)
- Xiang Li
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Daniel Heber
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Ivo Rausch
- Center for Medical Physics and Biomedical Engineering, General Hospital Vienna, Medical University of Vienna, Vienna, Austria
| | - Dietrich Beitzke
- Division of Cardiovascular and Interventional Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Marius E Mayerhoefer
- Division of General and Pediatric Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Sazan Rasul
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Michael Kreissl
- Department of Nuclear Medicine, Klinikum Augsburg, Augsburg, Germany
| | - Markus Mitthauser
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Wolfgang Wadsak
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Markus Hartenbach
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Alexander Haug
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Xiaoli Zhang
- Department of Nuclear Medicine, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China
| | - Christian Loewe
- Division of Cardiovascular and Interventional Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Thomas Beyer
- Center for Medical Physics and Biomedical Engineering, General Hospital Vienna, Medical University of Vienna, Vienna, Austria
| | - Marcus Hacker
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
| |
Collapse
|
22
|
Bai J, Wang JTW, Rubio N, Protti A, Heidari H, Elgogary R, Southern P, Al-Jamal WT, Sosabowski J, Shah AM, Bals S, Pankhurst QA, Al-Jamal KT. Triple-Modal Imaging of Magnetically-Targeted Nanocapsules in Solid Tumours In Vivo. Theranostics 2016; 6:342-56. [PMID: 26909110 PMCID: PMC4737722 DOI: 10.7150/thno.11918] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2015] [Accepted: 04/22/2015] [Indexed: 01/24/2023] Open
Abstract
Triple-modal imaging magnetic nanocapsules, encapsulating hydrophobic superparamagnetic iron oxide nanoparticles, are formulated and used to magnetically target solid tumours after intravenous administration in tumour-bearing mice. The engineered magnetic polymeric nanocapsules m-NCs are ~200 nm in size with negative Zeta potential and shown to be spherical in shape. The loading efficiency of superparamagnetic iron oxide nanoparticles in the m-NC was ~100%. Up to ~3- and ~2.2-fold increase in tumour uptake at 1 and 24 h was achieved, when a static magnetic field was applied to the tumour for 1 hour. m-NCs, with multiple imaging probes (e.g. indocyanine green, superparamagnetic iron oxide nanoparticles and indium-111), were capable of triple-modal imaging (fluorescence/magnetic resonance/nuclear imaging) in vivo. Using triple-modal imaging is to overcome the intrinsic limitations of single modality imaging and provides complementary information on the spatial distribution of the nanocarrier within the tumour. The significant findings of this study could open up new research perspectives in using novel magnetically-responsive nanomaterials in magnetic-drug targeting combined with multi-modal imaging.
Collapse
|
23
|
Truong QA, Gewirtz H. Cardiac PET-CT for monitoring medical and interventional therapy in patients with CAD: PET alone versus hybrid PET-CT? Curr Cardiol Rep 2014; 16:460. [PMID: 24464305 DOI: 10.1007/s11886-013-0460-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
This review focuses on optimal use of PET and PET-CT in monitoring medical and interventional therapy in patients with CAD. PET provides quantitative measurement of absolute myocardial blood flow and thus permits comprehensive physiological assessment of the coronary circulation. Hybrid PET-CT, in particular CCTA, adds anatomical information to maximal MBF measurement and so facilitates distinction of triple vessel focal epicardial disease from coronary microvascular disease or diffuse coronary atherosclerosis without focal stenoses. Hybrid PET-CT also may be of value in determining appropriateness and feasibility of percutaneous interventional therapy for chronic total coronary occlusion. PET alone, however, is the preferred modality to address functional status of the coronary circulation and response over time, if required, to medical or interventional therapy. CT at a minimum provides attenuation correction. More detailed CCTA should be added only when a well-defined need for anatomical information is required to answer the clinical question posed.
Collapse
Affiliation(s)
- Quynh A Truong
- Department of Medicine, Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Cardiac Unit/Yawkey 5E, 55 Fruit St, Boston, MA, 02114, USA
| | | |
Collapse
|
24
|
|
25
|
Abstract
Cardiac multimodality (hybrid) imaging can be obtained from a variety of techniques, such as nuclear medicine with single photon emission computed tomography (SPECT) and positron emission tomography (PET), or radiology with multislice computed tomography (CT), magnetic resonance (MR) and echography. They are typically combined in a side-by-side or fusion mode in order to provide functional and morphological data to better characterise coronary artery disease, with more proven efficacy than when used separately. The gained information is then used to guide revascularisation procedures. We present an up-to-date comprehensive overview of multimodality imaging already in clinical use, as well as a combination of techniques with promising or developing applications.
Collapse
|
26
|
Aryal S, Key J, Stigliano C, Landis MD, Lee DY, Decuzzi P. Positron emitting magnetic nanoconstructs for PET/MR imaging. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2014; 10:2688-2696. [PMID: 24639392 DOI: 10.1002/smll.201303933] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/27/2013] [Revised: 02/10/2014] [Indexed: 06/03/2023]
Abstract
Hybrid PET/MRI scanners have the potential to provide fundamental molecular, cellular, and anatomic information essential for optimizing therapeutic and surgical interventions. However, their full utilization is currently limited by the lack of truly multi-modal contrast agents capable of exploiting the strengths of each modality. Here, we report on the development of long-circulating positron-emitting magnetic nanoconstructs (PEM) designed to image solid tumors for combined PET/MRI. PEMs are synthesized by a modified nano-precipitation method mixing poly(lactic-co-glycolic acid) (PLGA), lipids, and polyethylene glycol (PEG) chains with 5 nm iron oxide nanoparticles (USPIOs). PEM lipids are coupled with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and subsequently chelated to (64)Cu. PEMs show a diameter of 140 ± 7 nm and a transversal relaxivity r2 of 265.0 ± 10.0 (mM × s)(-1), with a r2/r1 ratio of 123. Using a murine xenograft model bearing human breast cancer cell line (MDA-MB-231), intravenously administered PEMs progressively accumulate in tumors reaching a maximum of 3.5 ± 0.25% ID/g tumor at 20 h post-injection. Correlation of PET and MRI signals revealed non-uniform intratumoral distribution of PEMs with focal areas of accumulation at the tumor periphery. These long-circulating PEMs with high transversal relaxivity and tumor accumulation may allow for detailed interrogation over multiple scales in a clinically relevant setting.
Collapse
Affiliation(s)
- Santosh Aryal
- Department of Translational Imaging, Houston Methodist Research Institute, Houston, TX, 77030, USA
| | | | | | | | | | | |
Collapse
|
27
|
Shim CY, Lindner JR. Cardiovascular molecular imaging with contrast ultrasound: principles and applications. Korean Circ J 2014; 44:1-9. [PMID: 24497883 PMCID: PMC3905109 DOI: 10.4070/kcj.2014.44.1.1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Methods for imaging the molecular or cellular profile of tissue are being developed for all forms of non-invasive cardiovascular imaging. It is thought that these technologies will potentially improve patient outcomes by allowing diagnosis of disease at an early-stage, monitoring disease progression, providing important information on patient risk, and for tailoring therapy to the molecular basis of disease. Molecular imaging is also already assuming an important role in science by providing a better understanding of the molecular basis of cardiovascular pathology, for assessing response to new therapies, and for rapidly optimizing new or established therapies. Ultrasound-based molecular imaging is one of these new approaches. Contrast-enhanced ultrasound molecular imaging relies on the detection of novel site-targeted microbubbles (MB) or other acoustically active particles which are administered by intravenous injection, circulate throughout the vascular compartment, and are then retained and imaged within regions of disease by ligand-directed binding. The technique is thought to be advantageous in practical terms of cost, time, and ease of use. The aim of this review is to discuss the molecular participants of cardiovascular disease that have been targeted for ultrasound imaging, general features of site-targeted MB, imaging protocols, and potential roles of ultrasound molecular imaging in cardiovascular research and clinical medicine.
Collapse
Affiliation(s)
- Chi Young Shim
- Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA
| | - Jonathan R Lindner
- Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA
| |
Collapse
|
28
|
Bazzicalupi C, Bianchi A, García-España E, Delgado-Pinar E. Metals in supramolecular chemistry. Inorganica Chim Acta 2014. [DOI: 10.1016/j.ica.2014.03.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Teresa Albelda M, Garcia-España E, Frias JC. Visualizing the atherosclerotic plaque: a chemical perspective. Chem Soc Rev 2014; 43:2858-76. [PMID: 24526041 DOI: 10.1039/c3cs60410a] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Atherosclerosis is the major underlying pathologic cause of coronary artery disease. An early detection of the disease can prevent clinical sequellae such as angina, myocardial infarction, and stroke. The different imaging techniques employed to visualize the atherosclerotic plaque provide information of diagnostic and prognostic value. Furthermore, the use of contrast agents helps to improve signal-to-noise ratio providing better images. For nuclear imaging techniques and optical imaging these agents are absolutely necessary. We report on the different contrast agents that have been used, are used or may be used in future in animals, humans, or excised tissues for the distinct imaging modalities for atherosclerotic plaque imaging.
Collapse
Affiliation(s)
- Ma Teresa Albelda
- Universidad de Valencia, Instituto de Ciencia Molecular, Edificio de Institutos de Paterna, c/ Catedrático José Beltrán 2, 46071 Valencia, Spain
| | | | | |
Collapse
|
30
|
Sigalov AB. Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages. CONTRAST MEDIA & MOLECULAR IMAGING 2014; 9:372-82. [PMID: 24729189 DOI: 10.1002/cmmi.1587] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/25/2013] [Revised: 10/25/2013] [Accepted: 11/18/2013] [Indexed: 12/20/2022]
Abstract
Magnetic resonance imaging (MRI) of macrophages in atherosclerosis requires the use of contrast-enhancing agents. Reconstituted lipoprotein particles that mimic native high-density lipoproteins (HDL) are a versatile delivery platform for Gd-based contrast agents (GBCA) but require targeting moieties to direct the particles to macrophages. In this study, a naturally occurring methionine oxidation in the major HDL protein, apolipoprotein (apo) A-I, was exploited as a novel way to target HDL to macrophages. We also tested if fully functional GBCA-HDL can be generated using synthetic apo A-I peptides. The fluorescence and MRI studies reveal that specific oxidation of apo A-I or its peptides increases the in vitro macrophage uptake of GBCA-HDL by 2-3 times. The in vivo imaging studies using an apo E-deficient mouse model of atherosclerosis and a 3.0 T MRI system demonstrate that this modification significantly improves atherosclerotic plaque detection using GBCA-HDL. At 24 h post-injection of 0.05 mmol Gd kg(-1) GBCA-HDL containing oxidized apo A-I or its peptides, the atherosclerotic wall/muscle normalized enhancement ratios were 90 and 120%, respectively, while those of GBCA-HDL containing their unmodified counterparts were 35 and 45%, respectively. Confocal fluorescence microscopy confirms the accumulation of GBCA-HDL containing oxidized apo A-I or its peptides in intraplaque macrophages. Together, the results of this study confirm the hypothesis that specific oxidation of apo A-I targets GBCA-HDL to macrophages in vitro and in vivo. Furthermore, our observation that synthetic peptides can functionally replace the native apo A-I protein in HDL further encourages the development of these contrast agents for macrophage imaging.
Collapse
|
31
|
Molecular imaging of macrophage enzyme activity in cardiac inflammation. CURRENT CARDIOVASCULAR IMAGING REPORTS 2014; 7:9258. [PMID: 24729833 DOI: 10.1007/s12410-014-9258-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Molecular imaging is highly advantageous as various insidious inflammatory events can be imaged in a serial and quantitative fashion. Combined with the conventional imaging modalities like computed tomography (CT), magnetic resonance (MR) and nuclear imaging, it helps us resolve the extent of ongoing pathology, quantify inflammation and predict outcome. Macrophages are increasingly gaining importance as an imaging biomarker in inflammatory cardiovascular diseases. Macrophages, recruited to the site of injury, internalize necrotic or foreign material. Along with phagocytosis, activated macrophages release proteolytic enzymes like matrix metalloproteinases (MMPs) and cathepsins into the extracellular environment. Pro-inflammatory monocytes and macrophages also induce tissue oxidative damage through the inflammatory enzyme myeloperoxidase (MPO). In this review we will highlight recent advances in molecular macrophage imaging. Particular stress will be given to macrophage functional and enzymatic activity imaging which targets phagocytosis, proteolysis and myeloperoxidase activity imaging.
Collapse
|
32
|
Affiliation(s)
- Farouc A Jaffer
- Massachusetts General Hospital, Harvard Medical School, Cardiovascular Research Center, Boston, Massachusetts, USA
| | - Johan W Verjans
- Massachusetts General Hospital, Harvard Medical School, Cardiovascular Research Center, Boston, Massachusetts, USA Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, the Netherlands
| |
Collapse
|
33
|
Ardipradja K, Yeoh SD, Alt K, O'Keefe G, Rigopoulos A, Howells DW, Scott AM, Peter K, Ackerman U, Hagemeyer CE. Detection of activated platelets in a mouse model of carotid artery thrombosis with 18 F-labeled single-chain antibodies. Nucl Med Biol 2013; 41:229-37. [PMID: 24440583 DOI: 10.1016/j.nucmedbio.2013.12.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2013] [Revised: 11/14/2013] [Accepted: 12/07/2013] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Activated platelets are key players in thrombosis and inflammation. We previously generated single-chain antibodies (scFv) against ligand-induced binding sites (LIBS) on the highly abundant platelet glycoprotein integrin receptor IIb/IIIa. The aim of this study was the construction and characterisation of a novel (18)F PET radiotracer based on this antibody. METHODS ScFv(anti-LIBS) and control antibody mut-scFv were reacted with N-succinimidyl-4-[(18)F]fluorobenzoate (S[(18)F]FB). Radiolabeled scFv was incubated with in vitro formed platelet clots and injected into mice with FeCl(3) induced thrombus in the left carotid artery. Clots were imaged in the PET scanner and amount of radioactivity measured using an ionization chamber and image analysis. Assessment of vessel injury as well as the biodistribution of the radiolabeled scFv was studied. RESULTS After incubation with increasing concentrations of (18)F-scFv(anti-LIBS) clots had retained significantly higher amounts of radioactivity compared to clots incubated with radiolabeled (18)F-mut-scFv (13.3 ± 3.8 vs. 3.6 ± 1 KBq, p < 0.05, n = 9, decay corrected). In the in vivo experiments we found an high uptake of the tracer in the injured vessel compared with the non-injured vessel, with 12.6 ± 4.7% injected dose per gram (ID/g) uptake in the injured vessel and 3.7 ± 0.9% ID/g in the non-injured vessel 5 minutes after injection (p < 0.05, n = 6). CONCLUSIONS Our results show that the novel antibody radiotracer (18)F-scFv(anti-LIBS) is useful for the sensitive detection of activated platelets and thrombosis. ADVANCES IN KNOWLEDGE AND IMPLICATIONS FOR PATIENT CARE We describe the first (18)F variant of a scFv(anti-LIBS) against activated platelets. This diagnostic agent could provide a powerful tool for the assessment of acute thrombosis and inflammation in patients in the future.
Collapse
Affiliation(s)
- Katie Ardipradja
- Vascular Biotechnology Laboratory, Baker IDI, Melbourne, Australia; Atherothrombosis and Vascular Biology Laboratory, Baker IDI, Melbourne, Australia; Departments of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia; Department of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia
| | - Shinn Dee Yeoh
- Departments of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia
| | - Karen Alt
- Vascular Biotechnology Laboratory, Baker IDI, Melbourne, Australia; Atherothrombosis and Vascular Biology Laboratory, Baker IDI, Melbourne, Australia
| | - Graeme O'Keefe
- Departments of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia
| | - Angela Rigopoulos
- Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia
| | - David W Howells
- The Florey Institute of Neuroscience and Mental Health, Austin Hospital, Melbourne, Australia
| | - Andrew M Scott
- Departments of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia; Department of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia; Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia
| | - Karlheinz Peter
- Atherothrombosis and Vascular Biology Laboratory, Baker IDI, Melbourne, Australia; Central Clinical School, Monash University, Melbourne, Australia
| | - Uwe Ackerman
- Departments of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia; Department of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia; Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia
| | - Christoph E Hagemeyer
- Vascular Biotechnology Laboratory, Baker IDI, Melbourne, Australia; Central Clinical School, Monash University, Melbourne, Australia.
| |
Collapse
|
34
|
Abstract
Techniques for in vivo assessment of disease-related molecular changes are being developed for all forms of non-invasive cardiovascular imaging. The ability to evaluate tissue molecular or cellular phenotype in patients has the potential to not only improve diagnostic capabilities but to enhance clinical care either by detecting disease at an earlier stage when it is more amenable to therapy, or by guiding most appropriate therapies. These new techniques also can be used in research programs in order to characterize pathophysiology and as a surrogate endpoint for therapeutic efficacy. The most common approach for molecular imaging involves the creation of novel-targeted contrast agents that are designed so that their kinetic properties are different in disease tissues. The main focus of this review is not to describe all the different molecular imaging approaches that have been developed, but rather to describe the status of the field and highlight some of the clinical and research applications that molecular imaging will likely provide meaningful benefit. Specific target areas include assessment of atherosclerotic disease, tissue ischemia, and ventricular and vascular remodeling.
Collapse
Affiliation(s)
- Jonathan R Lindner
- Knight Cardiovascular Institute, Oregon Health & Science University, UHN-62, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239, USA,
| | | |
Collapse
|
35
|
Abstract
This review focuses on molecular imaging using various radioligands for the tissue characterization of patients with heart failure. 123I-labeled metaiodobenzylguanidine (MIBG), as a marker of adrenergic neuron function, plays an important role in risk stratification in heart failure and may be useful for predicting fatal arrhythmias that may require implantable cardioverter-defibrillator treatment. MIBG has also been used for monitoring treatment effects under various medications. Various positron emission tomography (PET) radioligands have been introduced for the quantitative assessment of presynaptic and postsynaptic neuronal function in vivo. 11C-hydroxyephedrine, like MIBG, has potential for assessing the severity of heart failure. Our PET study using the β-receptor antagonist 11C-CGP 12177 in patients with heart failure showed a reduction of β-receptor density, indicating downregulation, in most of the patients. More studies are needed to confirm the clinical utility of these molecular imaging modalities for the management of heart failure patients.
Collapse
|
36
|
Souron JB, Petiet A, Decup F, Tran XV, Lesieur J, Poliard A, Le Guludec D, Letourneur D, Chaussain C, Rouzet F, Opsahl Vital S. Pulp cell tracking by radionuclide imaging for dental tissue engineering. Tissue Eng Part C Methods 2013; 20:188-97. [PMID: 23789732 DOI: 10.1089/ten.tec.2013.0148] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Pulp engineering with dental mesenchymal stem cells is a promising therapy for injured teeth. An important point is to determine the fate of implanted cells in the pulp over time and particularly during the early phase following implantation. Indeed, the potential engraftment of the implanted cells in other organs has to be assessed, in particular, to evaluate the risk of inducing ectopic mineralization. In this study, our aim was to follow by nuclear imaging the radiolabeled pulp cells after implantation in the rat emptied pulp chamber. For that purpose, indium-111-oxine (¹¹¹In-oxine)-labeled rat pulp cells were added to polymerizing type I collagen hydrogel to obtain a pulp equivalent. This scaffold was implanted in the emptied pulp chamber space in the upper first rat molar. Labeled cells were then tracked during 3 weeks by helical single-photon emission computed tomography (SPECT)/computed tomography performed on a dual modality dedicated small animal camera. Negative controls were performed using lysed radiolabeled cells obtained in a hypotonic solution. In vitro data indicated that ¹¹¹In-oxine labeling did not affect cell viability and proliferation. In vivo experiments allowed a noninvasive longitudinal follow-up of implanted living cells for at least 3 weeks and indicated that SPECT signal intensity was related to implanted cell integrity. Notably, there was no detectable systemic release of implanted cells from the tooth. In addition, histological analysis of the samples showed mitotically active fibroblastic cells as well as neoangiogenesis and nervous fibers in pulp equivalents seeded with entire cells, whereas pulp equivalents prepared from lysed cells were devoid of cell colonization. In conclusion, our study demonstrates that efficient labeling of pulp cells can be achieved and, for the first time, that these cells can be followed up after implantation in the tooth by nuclear imaging. Furthermore, it appears that grafted cells retained the label and are viable to follow the repair process. This technique is expected to be of major interest for monitoring implanted cells in innovative therapies for injured teeth.
Collapse
Affiliation(s)
- Jean-Baptiste Souron
- 1 EA2496, Dental School, University Paris Descartes PRES Sorbonne Paris Cité , Montrouge, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Heidt T, Nahrendorf M. Multimodal iron oxide nanoparticles for hybrid biomedical imaging. NMR IN BIOMEDICINE 2013; 26:756-765. [PMID: 23065771 PMCID: PMC3549036 DOI: 10.1002/nbm.2872] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/02/2012] [Revised: 08/01/2012] [Accepted: 08/29/2012] [Indexed: 05/31/2023]
Abstract
Iron oxide core nanoparticles are attractive imaging agents because their material properties allow the tuning of pharmacokinetics as well as the attachment of multiple moieties to their surface. In addition to affinity ligands, these include fluorochromes and radioisotopes for detection with optical and nuclear imaging. As the iron oxide core can be detected by MRI, options for combining imaging modalities are manifold. Already, preclinical imaging strategies have combined noninvasive imaging with higher resolution techniques, such as intravital microscopy, to gain unprecedented insight into steady-state biology and disease. Going forward, hybrid iron oxide nanoparticles will help to merge modalities, creating a synergy that will enable imaging in basic research and, potentially, also in the clinic.
Collapse
Affiliation(s)
- Timo Heidt
- Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
| | - Matthias Nahrendorf
- Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
38
|
Bengel FM, George RT, Schuleri KH, Lardo AC, Wollert KC. Image-guided therapies for myocardial repair: concepts and practical implementation. Eur Heart J Cardiovasc Imaging 2013; 14:741-51. [PMID: 23720377 DOI: 10.1093/ehjci/jet038] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Cell- and molecule-based therapeutic strategies to support wound healing and regeneration after myocardial infarction (MI) are under development. These emerging therapies aim at sustained preservation of ventricular function by enhancing tissue repair after myocardial ischaemia and reperfusion. Such therapies will benefit from guidance with regard to timing, regional targeting, suitable candidate selection, and effectiveness monitoring. Such guidance is effectively obtained by non-invasive tomographic imaging. Infarct size, tissue characteristics, muscle mass, and chamber geometry can be determined by magnetic resonance imaging and computed tomography. Radionuclide imaging can be used for the tracking of therapeutic agents and for the interrogation of molecular mechanisms such as inflammation, angiogenesis, and extracellular matrix activation. This review article portrays the hypothesis that an integrated approach with an early implementation of structural and molecular tomographic imaging in the development of novel therapies will provide a framework for achieving the goal of improved tissue repair after MI.
Collapse
Affiliation(s)
- Frank M Bengel
- Department of Nuclear Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany.
| | | | | | | | | |
Collapse
|
39
|
Cardiac Micro-PET-CT. CURRENT CARDIOVASCULAR IMAGING REPORTS 2013. [DOI: 10.1007/s12410-012-9188-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
40
|
Quantitative Longitudinal Imaging of Vascular Inflammation and Treatment by Ezetimibe in apoE Mice by FMT Using New Optical Imaging Biomarkers of Cathepsin Activity and α(v)β(3) Integrin. INTERNATIONAL JOURNAL OF MOLECULAR IMAGING 2012; 2012:189254. [PMID: 23119157 PMCID: PMC3483711 DOI: 10.1155/2012/189254] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/23/2012] [Accepted: 09/06/2012] [Indexed: 12/02/2022]
Abstract
Inflammation as a core pathological event of atherosclerotic lesions is associated with the secretion of cathepsin proteases and the expression of αvβ3 integrin. We employed fluorescence molecular tomographic (FMT) noninvasive imaging of these molecular activities using cathepsin sensing (ProSense, CatB FAST) and αvβ3 integrin (IntegriSense) near-infrared fluorescence (NIRF) agents. A statistically significant increase in the ProSense and IntegriSense signal was observed within the chest region of apoE−/− mice (P < 0.05) versus C57BL/6 mice starting 25 and 22 weeks on high cholesterol diet, respectively. In a treatment study using ezetimibe (7 mg/kg), there was a statistically significant reduction in the ProSense and CatB FAST chest signal of treated (P < 0.05) versus untreated apoE−/− mice at 31 and 21 weeks on high cholesterol diet, respectively. The signal of ProSense and CatB FAST correlated with macrophage counts and was found associated with inflammatory cells by fluorescence microscopy and flow cytometry of cells dissociated from aortas. This report demonstrates that cathepsin and αvβ3 integrin NIRF agents can be used as molecular imaging biomarkers for longitudinal detection of atherosclerosis, and cathepsin agents can monitor anti-inflammatory effects of ezetimibe with applications in preclinical testing of therapeutics and potentially for early diagnosis of atherosclerosis in patients.
Collapse
|
41
|
Michalska M, Machtoub L, Manthey HD, Bauer E, Herold V, Krohne G, Lykowsky G, Hildenbrand M, Kampf T, Jakob P, Zernecke A, Bauer WR. Visualization of Vascular Inflammation in the Atherosclerotic Mouse by Ultrasmall Superparamagnetic Iron Oxide Vascular Cell Adhesion Molecule-1–Specific Nanoparticles. Arterioscler Thromb Vasc Biol 2012; 32:2350-7. [DOI: 10.1161/atvbaha.112.255224] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Objective—
Noninvasive imaging of atherosclerosis remains challenging in clinical applications. Here, we applied noninvasive molecular imaging to detect vascular cell adhesion molecule-1 in early and advanced atherosclerotic lesions of apolipoprotein E–deficient mice.
Methods and Results—
Ultrasmall superparamagnetic iron oxide particles functionalized with (P03011) or without (P3007) vascular cell adhesion molecule-1−binding peptide were visualized by ultra high-field (17.6 T) magnetic resonance. Injection of P03011 resulted in a marked signal loss in the aortic root of apolipoprotein E–deficient mice fed a Western diet for 8 and 26 weeks in vivo and ex vivo, compared with preinjection measurements, P3007-injected mice, and P03011- or P3007-injected age-matched C57BL/6 controls. Histological analyses revealed iron accumulations in the intima, in colocalization with vascular cell adhesion molecule-1−expressing macrophages and endothelial cells. Coherent anti-Stokes Raman scattering microscopy demonstrated iron signals in the intima and media of the aortic root in the P03011-injected but not untreated apolipoprotein E–deficient mice, localized to macrophages, luminal endothelial-like cells, and medial regions containing smooth muscle cells. Electron microscopy confirmed iron particles enclosed in endothelial cells and in the vicinity of smooth muscle cells.
Conclusion—
Using a combination of innovative imaging modalities, in this study, we demonstrate the feasibility of applying P03011 as a contrast agent for imaging of atherosclerosis.
Collapse
Affiliation(s)
- Marta Michalska
- From the Experimentelle Physik V, Universität Würzburg, Würzburg, Germany (M.M., V.H., G.L., T.K., P.J.); Medizinische Klinik und Poliklinik I, Universitätsklinik Würzburg, Würzburg, Germany (M.M., E.B., W.R.B.); Universitätsklinik für Radiodiagnostik, Innsbruck Medical University, Innsbruck, Austria (L.M.); Rudolf-Virchow-Zentrum für Experimentelle Biomedizin, Universität Würzburg, Würzburg, Germany (H.D.M., A.Z.); Biozentrum, Universität Würzburg, Würzburg, Germany (G.K.); MRB Research Center
| | - Lina Machtoub
- From the Experimentelle Physik V, Universität Würzburg, Würzburg, Germany (M.M., V.H., G.L., T.K., P.J.); Medizinische Klinik und Poliklinik I, Universitätsklinik Würzburg, Würzburg, Germany (M.M., E.B., W.R.B.); Universitätsklinik für Radiodiagnostik, Innsbruck Medical University, Innsbruck, Austria (L.M.); Rudolf-Virchow-Zentrum für Experimentelle Biomedizin, Universität Würzburg, Würzburg, Germany (H.D.M., A.Z.); Biozentrum, Universität Würzburg, Würzburg, Germany (G.K.); MRB Research Center
| | - Helga D. Manthey
- From the Experimentelle Physik V, Universität Würzburg, Würzburg, Germany (M.M., V.H., G.L., T.K., P.J.); Medizinische Klinik und Poliklinik I, Universitätsklinik Würzburg, Würzburg, Germany (M.M., E.B., W.R.B.); Universitätsklinik für Radiodiagnostik, Innsbruck Medical University, Innsbruck, Austria (L.M.); Rudolf-Virchow-Zentrum für Experimentelle Biomedizin, Universität Würzburg, Würzburg, Germany (H.D.M., A.Z.); Biozentrum, Universität Würzburg, Würzburg, Germany (G.K.); MRB Research Center
| | - Elisabeth Bauer
- From the Experimentelle Physik V, Universität Würzburg, Würzburg, Germany (M.M., V.H., G.L., T.K., P.J.); Medizinische Klinik und Poliklinik I, Universitätsklinik Würzburg, Würzburg, Germany (M.M., E.B., W.R.B.); Universitätsklinik für Radiodiagnostik, Innsbruck Medical University, Innsbruck, Austria (L.M.); Rudolf-Virchow-Zentrum für Experimentelle Biomedizin, Universität Würzburg, Würzburg, Germany (H.D.M., A.Z.); Biozentrum, Universität Würzburg, Würzburg, Germany (G.K.); MRB Research Center
| | - Volker Herold
- From the Experimentelle Physik V, Universität Würzburg, Würzburg, Germany (M.M., V.H., G.L., T.K., P.J.); Medizinische Klinik und Poliklinik I, Universitätsklinik Würzburg, Würzburg, Germany (M.M., E.B., W.R.B.); Universitätsklinik für Radiodiagnostik, Innsbruck Medical University, Innsbruck, Austria (L.M.); Rudolf-Virchow-Zentrum für Experimentelle Biomedizin, Universität Würzburg, Würzburg, Germany (H.D.M., A.Z.); Biozentrum, Universität Würzburg, Würzburg, Germany (G.K.); MRB Research Center
| | - Georg Krohne
- From the Experimentelle Physik V, Universität Würzburg, Würzburg, Germany (M.M., V.H., G.L., T.K., P.J.); Medizinische Klinik und Poliklinik I, Universitätsklinik Würzburg, Würzburg, Germany (M.M., E.B., W.R.B.); Universitätsklinik für Radiodiagnostik, Innsbruck Medical University, Innsbruck, Austria (L.M.); Rudolf-Virchow-Zentrum für Experimentelle Biomedizin, Universität Würzburg, Würzburg, Germany (H.D.M., A.Z.); Biozentrum, Universität Würzburg, Würzburg, Germany (G.K.); MRB Research Center
| | - Gunthard Lykowsky
- From the Experimentelle Physik V, Universität Würzburg, Würzburg, Germany (M.M., V.H., G.L., T.K., P.J.); Medizinische Klinik und Poliklinik I, Universitätsklinik Würzburg, Würzburg, Germany (M.M., E.B., W.R.B.); Universitätsklinik für Radiodiagnostik, Innsbruck Medical University, Innsbruck, Austria (L.M.); Rudolf-Virchow-Zentrum für Experimentelle Biomedizin, Universität Würzburg, Würzburg, Germany (H.D.M., A.Z.); Biozentrum, Universität Würzburg, Würzburg, Germany (G.K.); MRB Research Center
| | - Markus Hildenbrand
- From the Experimentelle Physik V, Universität Würzburg, Würzburg, Germany (M.M., V.H., G.L., T.K., P.J.); Medizinische Klinik und Poliklinik I, Universitätsklinik Würzburg, Würzburg, Germany (M.M., E.B., W.R.B.); Universitätsklinik für Radiodiagnostik, Innsbruck Medical University, Innsbruck, Austria (L.M.); Rudolf-Virchow-Zentrum für Experimentelle Biomedizin, Universität Würzburg, Würzburg, Germany (H.D.M., A.Z.); Biozentrum, Universität Würzburg, Würzburg, Germany (G.K.); MRB Research Center
| | - Thomas Kampf
- From the Experimentelle Physik V, Universität Würzburg, Würzburg, Germany (M.M., V.H., G.L., T.K., P.J.); Medizinische Klinik und Poliklinik I, Universitätsklinik Würzburg, Würzburg, Germany (M.M., E.B., W.R.B.); Universitätsklinik für Radiodiagnostik, Innsbruck Medical University, Innsbruck, Austria (L.M.); Rudolf-Virchow-Zentrum für Experimentelle Biomedizin, Universität Würzburg, Würzburg, Germany (H.D.M., A.Z.); Biozentrum, Universität Würzburg, Würzburg, Germany (G.K.); MRB Research Center
| | - Peter Jakob
- From the Experimentelle Physik V, Universität Würzburg, Würzburg, Germany (M.M., V.H., G.L., T.K., P.J.); Medizinische Klinik und Poliklinik I, Universitätsklinik Würzburg, Würzburg, Germany (M.M., E.B., W.R.B.); Universitätsklinik für Radiodiagnostik, Innsbruck Medical University, Innsbruck, Austria (L.M.); Rudolf-Virchow-Zentrum für Experimentelle Biomedizin, Universität Würzburg, Würzburg, Germany (H.D.M., A.Z.); Biozentrum, Universität Würzburg, Würzburg, Germany (G.K.); MRB Research Center
| | - Alma Zernecke
- From the Experimentelle Physik V, Universität Würzburg, Würzburg, Germany (M.M., V.H., G.L., T.K., P.J.); Medizinische Klinik und Poliklinik I, Universitätsklinik Würzburg, Würzburg, Germany (M.M., E.B., W.R.B.); Universitätsklinik für Radiodiagnostik, Innsbruck Medical University, Innsbruck, Austria (L.M.); Rudolf-Virchow-Zentrum für Experimentelle Biomedizin, Universität Würzburg, Würzburg, Germany (H.D.M., A.Z.); Biozentrum, Universität Würzburg, Würzburg, Germany (G.K.); MRB Research Center
| | - Wolfgang R. Bauer
- From the Experimentelle Physik V, Universität Würzburg, Würzburg, Germany (M.M., V.H., G.L., T.K., P.J.); Medizinische Klinik und Poliklinik I, Universitätsklinik Würzburg, Würzburg, Germany (M.M., E.B., W.R.B.); Universitätsklinik für Radiodiagnostik, Innsbruck Medical University, Innsbruck, Austria (L.M.); Rudolf-Virchow-Zentrum für Experimentelle Biomedizin, Universität Würzburg, Würzburg, Germany (H.D.M., A.Z.); Biozentrum, Universität Würzburg, Würzburg, Germany (G.K.); MRB Research Center
| |
Collapse
|
42
|
Affiliation(s)
- Denis B Buxton
- Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Bethesda, MD 20817, USA.
| |
Collapse
|
43
|
de Barros AB, Tsourkas A, Saboury B, Cardoso VN, Alavi A. Emerging role of radiolabeled nanoparticles as an effective diagnostic technique. EJNMMI Res 2012; 2:39. [PMID: 22809406 PMCID: PMC3441881 DOI: 10.1186/2191-219x-2-39] [Citation(s) in RCA: 97] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2012] [Accepted: 07/05/2012] [Indexed: 12/19/2022] Open
Abstract
Nanomedicine is emerging as a promising approach for diagnostic applications. Nanoparticles are structures in the nanometer size range, which can present different shapes, compositions, charges, surface modifications, in vitro and in vivo stabilities, and in vivo performances. Nanoparticles can be made of materials of diverse chemical nature, the most common being metals, metal oxides, silicates, polymers, carbon, lipids, and biomolecules. Nanoparticles exist in various morphologies, such as spheres, cylinders, platelets, and tubes. Radiolabeled nanoparticles represent a new class of agent with great potential for clinical applications. This is partly due to their long blood circulation time and plasma stability. In addition, because of the high sensitivity of imaging with radiolabeled compounds, their use has promise of achieving accurate and early diagnosis. This review article focuses on the application of radiolabeled nanoparticles in detecting diseases such as cancer and cardiovascular diseases and also presents an overview about the formulation, stability, and biological properties of the nanoparticles used for diagnostic purposes.
Collapse
|
44
|
Molecular Imaging of Left Ventricular Remodeling. CURRENT CARDIOVASCULAR IMAGING REPORTS 2012. [DOI: 10.1007/s12410-012-9137-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
45
|
Ransohoff JD, Wu JC. Imaging stem cell therapy for the treatment of peripheral arterial disease. Curr Vasc Pharmacol 2012; 10:361-73. [PMID: 22239638 PMCID: PMC3683543 DOI: 10.2174/157016112799959404] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2011] [Revised: 06/28/2011] [Accepted: 10/19/2011] [Indexed: 01/08/2023]
Abstract
Arteriosclerotic cardiovascular diseases are among the leading causes of morbidity and mortality worldwide. Therapeutic angiogenesis aims to treat ischemic myocardial and peripheral tissues by delivery of recombinant proteins, genes, or cells to promote neoangiogenesis. Concerns regarding the safety, side effects, and efficacy of protein and gene transfer studies have led to the development of cell-based therapies as alternative approaches to induce vascular regeneration and to improve function of damaged tissue. Cell-based therapies may be improved by the application of imaging technologies that allow investigators to track the location, engraftment, and survival of the administered cell population. The past decade of investigations has produced promising clinical data regarding cell therapy, but design of trials and evaluation of treatments stand to be improved by emerging insight from imaging studies. Here, we provide an overview of pre-clinical and clinical experience using cell-based therapies to promote vascular regeneration in the treatment of peripheral arterial disease. We also review four major imaging modalities and underscore the importance of in vivo analysis of cell fate for a full understanding of functional outcomes.
Collapse
Affiliation(s)
- Julia D. Ransohoff
- Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA
- Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Joseph C. Wu
- Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA
- Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA
- Institute of Regenerative Medicine and Stem Cell Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
| |
Collapse
|
46
|
Liu Y, Welch MJ. Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications. Bioconjug Chem 2012; 23:671-82. [PMID: 22242601 PMCID: PMC3329595 DOI: 10.1021/bc200264c] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Over the past decade, positron emitter labeled nanoparticles have been widely used in and substantially improved for a range of diagnostic biomedical research. However, given growing interest in personalized medicine and translational research, a major challenge in the field will be to develop disease-specific nanoprobes with facile and robust radiolabeling strategies and that provide imaging stability, enhanced sensitivity for disease early stage detection, optimized in vivo pharmacokinetics for reduced nonspecific organ uptake, and improved targeting for elevated efficacy. This review briefly summarizes the major applications of nanoparticles labeled with positron emitters for cardiovascular imaging, lung diagnosis, and tumor theranostics.
Collapse
Affiliation(s)
- Yongjian Liu
- Department of Radiology, Washington University in St. Louis, Missouri 63110, USA.
| | | |
Collapse
|
47
|
Camici PG, Rimoldi OE, Gaemperli O, Libby P. Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque. Eur Heart J 2012; 33:1309-17. [PMID: 22507974 DOI: 10.1093/eurheartj/ehs067] [Citation(s) in RCA: 77] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Over the last several decades, basic cardiovascular research has significantly enhanced our understanding of pathobiological processes leading to formation, progression, and complications of atherosclerotic plaques. By harnessing these advances in cardiovascular biology, imaging has advanced beyond its traditional anatomical domains to a tool that permits probing of particular molecular structures to image cellular behaviour and metabolic pathways involved in atherosclerosis. From the nascent atherosclerotic plaque to the death of inflammatory cells, several potential molecular and micro-anatomical targets for imaging with particular selective imaging probes and with a variety of imaging modalities have emerged from preclinical and animal investigations. Yet, substantive barriers stand between experimental use and wide clinical application of these novel imaging strategies. Each of the imaging modalities described herein faces hurdles-for example, sensitivity, resolution, radiation exposure, reproducibility, availability, standardization, or costs. This review summarizes the published literature reporting on functional imaging of vascular inflammation in atherosclerotic plaques emphasizing those techniques that have the greatest and/or most immediate potential for broad application in clinical practice. The prospective evaluation of these techniques and standardization of protocols by multinational networks could serve to determine their added value in clinical practice and guide their development and deployment.
Collapse
Affiliation(s)
- Paolo G Camici
- Vita-Salute University and Scientific Institute San Raffaele, Via Olgettina 60, Milan, Italy.
| | | | | | | |
Collapse
|
48
|
Miyama N, Dua MM, Schultz GM, Kosuge H, Terashima M, Pisani LJ, Dalman RL, McConnell MV. Bioluminescence and Magnetic Resonance Imaging of Macrophage Homing to Experimental Abdominal Aortic Aneurysms. Mol Imaging 2012. [DOI: 10.2310/7290.2011.00033] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Macrophage infiltration is a prominent feature of abdominal aortic aneurysm (AAA) progression. We used a combined imaging approach with bioluminescence (BLI) and magnetic resonance imaging (MRI) to study macrophage homing and accumulation in experimental AAA disease. Murine AAAs were created via intra-aortic infusion of porcine pancreatic elastase. Mice were imaged over 14 days after injection of prepared peritoneal macrophages. For BLI, macrophages were from transgenic mice expressing luciferase. For MRI, macrophages were labeled with iron oxide particles. Macrophage accumulation during aneurysm progression was observed by in situ BLI and by in vivo 7T MRI. Mice were sacrificed after imaging for histologic analysis. In situ BLI ( n = 32) demonstrated high signal in the AAA by days 7 and 14, which correlated significantly with macrophage number and aortic diameter. In vivo 7T MRI ( n = 13) at day 14 demonstrated T2* signal loss in the AAA and not in sham mice. Immunohistochemistry and Prussian blue staining confirmed the presence of injected macrophages in the AAA. BLI and MRI provide complementary approaches to track macrophage homing and accumulation in experimental AAAs. Similar dual imaging strategies may aid the study of AAA biology and the evaluation of novel therapies.
Collapse
Affiliation(s)
- Noriyuki Miyama
- From the Divisions of Vascular Surgery and Cardiovascular Medicine and the Department of Radiology, Stanford University School of Medicine, Stanford, CA
| | - Monica M. Dua
- From the Divisions of Vascular Surgery and Cardiovascular Medicine and the Department of Radiology, Stanford University School of Medicine, Stanford, CA
| | - Geoffrey M. Schultz
- From the Divisions of Vascular Surgery and Cardiovascular Medicine and the Department of Radiology, Stanford University School of Medicine, Stanford, CA
| | - Hisanori Kosuge
- From the Divisions of Vascular Surgery and Cardiovascular Medicine and the Department of Radiology, Stanford University School of Medicine, Stanford, CA
| | - Masahiro Terashima
- From the Divisions of Vascular Surgery and Cardiovascular Medicine and the Department of Radiology, Stanford University School of Medicine, Stanford, CA
| | - Laura J. Pisani
- From the Divisions of Vascular Surgery and Cardiovascular Medicine and the Department of Radiology, Stanford University School of Medicine, Stanford, CA
| | - Ronald L. Dalman
- From the Divisions of Vascular Surgery and Cardiovascular Medicine and the Department of Radiology, Stanford University School of Medicine, Stanford, CA
| | - Michael V. McConnell
- From the Divisions of Vascular Surgery and Cardiovascular Medicine and the Department of Radiology, Stanford University School of Medicine, Stanford, CA
| |
Collapse
|
49
|
Abstract
'Multimodality' imaging--the side-by-side interpretation of data obtained from various noninvasive imaging techniques, such as echocardiography, radionuclide techniques, multidetector CT (MDCT), and MRI--allows anatomical, morphological, and functional data to be combined, increases diagnostic accuracy, and improves the efficacy of cardiovascular interventions and clinical outcomes. During the past decade, advances in software and hardware have allowed co-registration of various imaging modalities, resulting in cardiac 'hybrid' or 'fusion' imaging. In this Review, we discuss the roles of both multimodality and hybrid imaging in three broad areas of cardiology--coronary artery disease (CAD), heart failure, and valvular heart disease. In the evaluation of CAD, integration of either single-photon emission computed tomography (SPECT) or PET with CT coronary angiography provides both morphological and functional data in a single procedure. Accordingly, the functional consequences (myocardial hypoperfusion on SPECT or PET) of anatomical pathology (coronary anatomy on MDCT or MRI) can be assessed. Co-registration of PET and MRI data sets to provide cellular and molecular information on plaque composition and stability is now possible. Furthermore, novel imaging modalities have been implemented to guide electrophysiological and transcatheter-based procedures, such as cardiac resynchronization therapy (an established treatment for patients with heart failure), and transcatheter valve repair or replacement procedures.
Collapse
|
50
|
Lee JS, Vendrell M, Chang YT. Diversity-oriented optical imaging probe development. Curr Opin Chem Biol 2011; 15:760-7. [DOI: 10.1016/j.cbpa.2011.10.007] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2011] [Revised: 10/04/2011] [Accepted: 10/17/2011] [Indexed: 12/13/2022]
|